Not Yet RecruitingNot Applicable

Implementation of the COmmunity HEalth System InnovatiON Project in Low- and Middle- Income Countries

Mozambique, Nepal, Peru2,094 participantsStarted 2025-05-17

Plain-language summary

The COHESION-I project will evaluate the effects of the co-creation intervention (2016 to 2019) and the co-design intervention (2023 to 2024) on improving (a) health system responsiveness, and (b) patient satisfaction, at the primary health care level, in Peru, Nepal and Mozambique, in relation to chronic diseases (hypertension, and diabetes mellitus), as well as specific neglected tropical diseases. Each intervention has been tailored to the context and characteristics of each one of the aforementioned low- and middle-income countries. For this quasi-experimental study, three arms were established: the co-creation (2016 to 2019) + co-design (2023 to 2024) arm; the co-design only (2023 to 2024) arm; and the control group (no intervention; usual care). The evaluation will be composed of four types of evaluations: quantitative; qualitative; economic; and process evaluation

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria for PHC users with diabetes, hypertension, and/or NTDs: * Males or females aged 18 years and over, from the selected sites * Having used the health services in the previous three months * Diagnosis (or estimated risk) of diabetes mellitus type 2, hypertension, or neurocysticercosis * Must be able to listen to radio programs, or other audio material Inclusion Criteria for PHC users without diabetes, hypertension, and/or NTDs: * Males or females aged 18 years and over, from the selected sites * Having used the health services in the previous three months * Must be able to listen to radio programs, or other audio material Exclusion Criteria for PHC users without diabetes, hypertension, and/or NTDs: \- Diagnosis (or estimated risk) of diabetes mellitus type 2, hypertension, or neurocysticercosis The criteria mentioned above refer solely to the quantitative evaluation. For the other types of evaluation, some different populations will be included (such as healthcare workers, local authorities and other stakeholders).

What they're measuring

Patient Satisfaction (PS)

Timeframe: Month 1 (baseline), Month 5 (pre-intervention), Month 9 (pre-intervention), Month 13 (during intervention), Month 17 (post-intervention), Month 21 (follow-up)

Health System Responsiveness (HSR)

Timeframe: Month 1 (baseline), Month 9 (pre-intervention), Month 13 (during intervention), Month 17 (post-intervention)

Quality of Life (QoL)

Timeframe: Month 1 (baseline), Month 9 (pre-intervention), Month 21 (follow-up)

Trial details

NCT IDNCT06989502

SponsorUniversidad Peruana Cayetano Heredia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-10-31

Contact for this trial

María Lazo-Porras, MD, MSc, PhD

511-2416978 maria.lazo@upch.pe

View on ClinicalTrials.gov More Hypertension trials